Stephen Hanauer to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Stephen Hanauer has written about Antibodies, Monoclonal, Humanized.
Connection Strength
2.043
-
Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
Score: 0.269
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
Score: 0.156
-
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.
Score: 0.131
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
Score: 0.130
-
Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
Score: 0.115
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
Score: 0.080
-
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4.
Score: 0.078
-
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
Score: 0.078
-
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
Score: 0.075
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710.
Score: 0.074
-
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21.
Score: 0.074
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.071
-
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
Score: 0.063
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.062
-
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
Score: 0.062
-
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
Score: 0.059
-
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
Score: 0.055
-
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11.
Score: 0.047
-
General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
Score: 0.046
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
Score: 0.044
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
Score: 0.038
-
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40.
Score: 0.021
-
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28.
Score: 0.017
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
Score: 0.016
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
Score: 0.015
-
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93.
Score: 0.015
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
Score: 0.015
-
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
Score: 0.015
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.
Score: 0.015
-
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
Score: 0.014
-
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
Score: 0.014
-
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22.
Score: 0.012
-
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
Score: 0.012
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
Score: 0.012
-
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
Score: 0.012
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
Score: 0.012
-
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
Score: 0.011
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
Score: 0.010